Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05996471
Other study ID # 209639
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date August 17, 2023
Est. completion date May 25, 2026

Study information

Verified date June 2024
Source ViiV Healthcare
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study aims at evaluating the efficacy of VH3810109, dosed in accordance with the dosing schedule as either intravenous (IV) infusion or subcutaneous (SC) infusion with recombinant hyaluronidase (rHuPH20), in combination with cabotegravir (CAB) intramuscular (IM) dosed in accordance with the dosing schedule in virologically suppressed, Antiretroviral therapy (ART)-experienced adult participants living with HIV.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 99
Est. completion date May 25, 2026
Est. primary completion date November 28, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion criteria Age 1. Participant must be 18 to 70 years of age inclusive, at the time of signing the informed consent. Type of Participant and Disease Characteristics 2. Must be on uninterrupted current regimen for at least 6 months prior to Screening. Any prior switch, defined as a change of a single drug or multiple drugs simultaneously, must have occurred due to tolerability/safety, access to medications, or convenience/simplification, and must NOT have been done for treatment failure (HIV-1 RNA =200 c/mL). Acceptable stable - ARV regimens prior to Screening include at least one NRTI plus: - INI - NNRTI - Boosted PI (or atazanavir [ATV] unboosted) - Excludes current use of cabotegravir or fostemsavir The addition, removal, or switch of a drug(s) that has been used to treat HIV based on antiretroviral properties of the drug constitutes a change in ART with the following limited exceptions: - Historical changes in formulations of ART drugs or booster drugs will not constitute a change in ART regimen if the data support similar exposures and efficacy, and the change must have been at least 3 months prior to Screening. - Historical maternal perinatal use of an NRTI when given in addition to an ongoing HAART will not be considered a change in ART regimen. - A change in dosing scheme of the same drug from twice daily to once daily will not be considered a change in ART regimen if data support similar exposures and efficacy. 3. Documented evidence of at least two plasma HIV-1 RNA measurements <50 c/mL in the 12 months prior to Screening: one within the 6 to 12-month window, and one within 6 months prior to Screening; 4. Plasma HIV-1 RNA <50 c/mL at Screening; 5. Screening CD4+ T-cell count =350 cells/mm3: Weight 6. Body weight >=50 kg to <=115 kg. Sex 7. Male and/or female Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies, assuring minimal contraception requirements noted below. All participants participating in the study should be counselled on safer sexual practices including the use and benefit/risk of effective barrier methods (e.g. male condom) and on the risk of HIV transmission to an uninfected partner. 1. Participants who are female at birth are eligible to participate if at least one of the following conditions applies: - Not pregnant or breastfeeding and at least one of the following conditions applies: - Is not a participant of childbearing potential (POCBP). OR - Is a POCBP and using an acceptable contraceptive method during the intervention period (at a minimum until after the last dose of study intervention). The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention. - A POCBP must have a negative highly sensitive (see Section 10.4) pregnancy test (urine or serum as required by local regulations) on Day 1, prior to the first dose of study intervention. * If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive. - The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a POCBP with an early undetected pregnancy. QTc 8. QTc Interval <450 msec. Phenotypic Sensitivity 9. Viral phenotypic sensitivity to VH3810109 based on IC90 of <=2 ug/mL and a Maximum Percent Inhibition >98% using the Monogram PhenoSense mAb Assay on sample obtained at a screening visit. Informed Consent 10. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Exclusion Criteria: Medical conditions: • Participants who are pregnant, breastfeeding, plan to become pregnant or breastfeed during the study - Participants having skin disease or disorder (i.e. infection, inflammation, dermatitis, eczema, drug rash, drug allergy, psoriasis, food allergy, urticaria) or tattoo overlying potential injection sites which may interfere with interpretation of injection site reactions or administration of VH3810109 or CAB - Participant has a gluteal implant/enhancement (including fillers) overlying the gluteus area or any other area which may significantly interfere with interpretation of injection site reactions - Participants with known history of cirrhosis with or without viral hepatitis co-infection - Participants with ongoing or clinically relevant pancreatitis - Untreated syphilis infection (positive rapid plasma reagin (RPR) at screening) without documentation of treatment. Participants who are at least 7 days post completed treatment are eligible if recruitment is open - Prior receipt of licensed or investigational HIV monoclonal antibody - Any evidence of an active Centers for Disease Control and Prevention (CDC) Stage 3 disease except cutaneous Kaposi's sarcoma not requiring systemic therapy. Historical or current CD4 cell counts less than 200 cells/mm^3 are not exclusionary - History of sensitivity to any of the study medications or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation - Any condition which, in the opinion of the investigator, may interfere with the absorption, distribution, metabolism or excretion of the study drugs, cART or render the participant unable to take oral medication - Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening - Previous exposure to cabotegravir - Participant enrolled in a prior or concurrent clinical study that includes a drug intervention within the last 30 days - Participants with ongoing chronic hepatitis B virus infection - Participants with hepatitis C co-infection - Participants who in the investigator's judgment, pose a significant suicidality risk - Contraindications, as per the current Prescribing Information for cabotegravir. - Previous hypersensitivity reaction to cabotegravir or - Contraindicated co-administered drugs: - Anticonvulsants: Carbamazepine, oxcarbazepine, phenobarbital, phenytoin - Antimycobacterials: Rifabutin, rifampin, rifapentine - Glucocorticoid (systemic): Dexamethasone (more than a single-dose treatment) - Herbal product: St John's wort (Hypericum perforatum) Prior/Concomitant Therapy: • Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening. - Previous exposure to cabotegravir. - Treatment with any of the following agents within 60 days of screening: -radiation therapy; -cytotoxic chemotherapeutic agents; -any systemic immune suppressant. - Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of study medication. - Current or anticipated need for chronic anti-coagulants. - Participants receiving any prohibited medication and who are unwilling or unable to switch to an alternate medication. Prior/Concurrent Clinical Study Experience • Participant enrolled in a prior or concurrent clinical study that includes a drug intervention within the last 30 days. Diagnostic Assessments • Any acute laboratory abnormality at Screening, which, in the opinion of the investigator, would preclude the participants inclusion in the study of an investigational compound. • Any evidence of viral resistance based on the presence of any major cabotegravir resistance-associated mutation [IAS-USA, 2022] in any historic resistance test result. • Any verified Grade 4 laboratory abnormality with the exception of Grade 4 triglycerides or lipid abnormalities. A single repeat test is allowed during the Screening period to verify a result. • Alanine aminotransferase (ALT) .3 times the upper limit of normal (ULN) - Creatinine clearance of <50 mL/min/1.73 m2 via using the refitted, race-neutral Chronic Kidney Disease Epidemiology Collaboration (CKD-EPIcr_R) method. - PT .Grade 2 (.1.25 ULN). A single repeat test is allowed during the Screening period to verify a result. Other Exclusion Criteria • To assess any potential impact on participant eligibility with regard to safety, the investigator must refer to the IB and supplements, approved product labels, and/or local prescribing information for detailed information regarding warnings, precautions, contraindications, AEs, drug interactions, and other significant data pertaining to the study drugs.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
VH3810109
VH3810109 will be administered.
Drug:
Cabotegravir
Cabotegravir will be administered.
Standard of care (SOC)
Pre-baseline SOC antiretroviral therapy (ART) will be administered.
Biological:
rHuPH20
rHuPH20 will be administered.

Locations

Country Name City State
Puerto Rico GSK Investigational Site San Juan
Puerto Rico GSK Investigational Site San Juan
United States GSK Investigational Site Albuquerque New Mexico
United States GSK Investigational Site Austin Texas
United States GSK Investigational Site Bakersfield California
United States GSK Investigational Site Birmingham Alabama
United States GSK Investigational Site Boston Massachusetts
United States GSK Investigational Site Bronx New York
United States GSK Investigational Site Bronx New York
United States GSK Investigational Site Chicago Illinois
United States GSK Investigational Site Cincinnati Ohio
United States GSK Investigational Site Columbia Missouri
United States GSK Investigational Site Dallas Texas
United States GSK Investigational Site Decatur Georgia
United States GSK Investigational Site El Paso Texas
United States GSK Investigational Site Fort Lauderdale Florida
United States GSK Investigational Site Fort Pierce Florida
United States GSK Investigational Site Greensboro North Carolina
United States GSK Investigational Site Houston Texas
United States GSK Investigational Site Houston Texas
United States GSK Investigational Site Los Angeles California
United States GSK Investigational Site Los Angeles California
United States GSK Investigational Site Manhasset New York
United States GSK Investigational Site Miami Florida
United States GSK Investigational Site Milwaukee Wisconsin
United States GSK Investigational Site Nashville Tennessee
United States GSK Investigational Site New Haven Connecticut
United States GSK Investigational Site New York New York
United States GSK Investigational Site New York New York
United States GSK Investigational Site Newark New Jersey
United States GSK Investigational Site Orlando Florida
United States GSK Investigational Site Palm Springs California
United States GSK Investigational Site Pensacola Florida
United States GSK Investigational Site Philadelphia Pennsylvania
United States GSK Investigational Site Portland Oregon
United States GSK Investigational Site Sacramento California
United States GSK Investigational Site San Francisco California
United States GSK Investigational Site Santa Fe New Mexico
United States GSK Investigational Site Sarasota Florida
United States GSK Investigational Site Southfield Michigan
United States GSK Investigational Site Springfield Massachusetts
United States GSK Investigational Site Vero Beach Florida
United States GSK Investigational Site Washington District of Columbia
United States GSK Investigational Site Washington District of Columbia
United States GSK Investigational Site West Palm Beach Florida

Sponsors (1)

Lead Sponsor Collaborator
ViiV Healthcare

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Plasma HIV-1 Ribonucleic acid (RNA) Greater Than or Equal to (=)50 Copies per Millilitre (c/mL) per Snapshot Algorithm at Month 6 Month 6
Secondary Number of Participants with Serious Adverse Events (SAEs), Deaths, and Adverse Events (AEs) Leading to Discontinuation of Investigational Product (IP) Up to Month 24
Secondary Number of Participants with Grade 3-4 AEs Up to Month 24
Secondary Number of Participants with Laboratory Abnormalities Up to Month 24
Secondary Number of Participants with Grade 1-4 Injection Site Reactions Up to Month 24
Secondary Number of Participants Meeting Confirmed Virologic Failure (CVF) Criteria Through Month 24 Up to Month 24
Secondary Number of Participants with Plasma HIV-1 RNA =50 c/mL per Snapshot Algorithm Over Time Up to Month 24
Secondary Number of Participants with Plasma HIV-1 RNA Less Than (<)50 c/mL per Snapshot Algorithm Over Time Up to Month 24
Secondary Number of Participants with HIV Disease Progression Up to Month 24
Secondary Serum Concentrations of VH3810109 Up to Month 24
Secondary Plasma Concentrations of Cabotegravir Up to Month 24
Secondary Absolute Value for Cluster of Differentiation 4 (CD4+) T-Cell Count Up to Month 24
Secondary Change From Baseline in CD4+ T-Cell Count Baseline (Day 1) and up to Month 24
Secondary Absolute Value for Cluster of Differentiation 8 (CD8+) T-Cell Count Up to Month 24
Secondary Change From Baseline in CD8+ T-Cell Count Baseline (Day 1) up to Month 24
Secondary Number of Participants with Anti-VH3810109 Antibodies Up to Month 24
Secondary Number of Participants with Neutralizing Antibodies Against VH3810109 Up to Month 24
Secondary Number of Participants with Treatment-emergent Genotypic Resistance Up to Month 24
Secondary Number of Participants with Treatment-emergent Phenotypic Resistance Up to Month 24
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2